BLS Pharmaceuticals Limited completed its evolution into an international pharmaceutical manufacturer in FY26, delivering $74.2 million in revenue and $19.0 million in Adjusted EBITDA at an approximate 26% margin.

BLS Pharmaceuticals Limited (ASX:BLS) is an Australian pharmaceutical company focused on the manufacture, development and commercialisation of regulated therapeutic products and active pharmaceutical ingredients. Through its wholly owned subsidiary, Breathe Life Sciences, the Company operates a GMP-licensed manufacturing, import, export and distribution platform spanning medicinal cannabis, psychedelic medicines and other controlled pharmaceutical products. BLS maintains operations across Australia, Europe, the United Kingdom and Japan, supplying pharmaceutical products and manufacturing services to regulated international markets through a growing network of commercial partners. In 2023 BLS was acquired by Bioxyne (BXN:ASX) and more recently, in June 2026, changed its name from Bioxyne Limited to BLS Pharmaceuticals Limited. A new era. A new name. Same vision. To redefine medicine.